It has been demonstrated that treatment with the antibody-drug-conjugate Indatuximab ravtansine (BT062), either alone or combined with docetaxel or paclitaxel to specifically target SDC1 (CD138)-expressing cells, results in marked tumor regression in vitro and in different triple-negative breast cancer patient-derived xenograft models [159]. The gene discussed is SDC1; the disease is triple-negative breast carcinoma.